Memorial Sloan Kettering Cancer Center: Plasmacytoma trials

The registry lists 17 Plasmacytoma studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 10Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaTerminatedNCT00567229Phase 2Results posted
• Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic AmyloidosisCompletedNCT00458822Phase 2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple MyelomaCompletedNCT00458705Phase 2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 2
• A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone PlasmacytomaWithdrawnNCT03196401Phase 1
• Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic AmyloidosisCompletedNCT00089167Phase 2
• Pyroxamide in Treating Patients With Advanced CancerCompletedNCT00042900Phase 1
• Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell TransplantationCompletedNCT00014482Not applicable
• Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple MyelomaCompletedNCT00008268Phase 2
• Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple MyelomaCompletedNCT00008242Phase 2
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerCompletedNCT00006019Phase 2
• St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
• Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyCompletedNCT00005634Phase 1
• Arsenic Trioxide in Treating Patients With Advanced Hematologic CancerCompletedNCT00003395Phase 1
• Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyCompletedNCT00003341Phase 3
• Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeCompletedNCT00002502Phase 2